Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

What are the liver enzyme requirements for starting terbinafine
Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration
Ozempic jordan price 2026

Lorazepam 2 mg/ml oral concentrate?

See the DrugPatentWatch profile for Lorazepam

Lorazepam (oral solution – 2 mg /mL)
Lorazepam is a short‑acting benzodiazepine used mainly for anxiety, acute seizures, pre‑operative sedation, and sometimes for alcohol withdrawal. The 2 mg /mL concentration is a common strength for oral solutions, allowing precise dosing for adults and children.

1. How it’s used

Indication Typical adult dose (oral solution) Typical pediatric dose (≤ 12 yrs)
Generalised anxiety disorder 1–2 mg PO q6–8 h; max 4 mg/day 0.05–0.1 mg/kg PO q6–8 h; max 1–2 mg/day
Acute seizures, status epilepticus 1 mg PO (or 0.2 mg/kg) → repeat once 0.02–0.05 mg/kg PO → repeat 1–2 h if needed
Pre‑operative sedation 0.5–1 mg PO 30 min before procedure 0.05–0.1 mg/kg PO 30 min before
Alcohol withdrawal 1–2 mg PO q4–6 h; taper over 3–5 days 0.05–0.1 mg/kg PO q4–6 h; taper
  • Administration: Shake well; measure with a syringe or dosing spoon. Do not dilute with other beverages unless directed by a clinician.
  • Titration: Start low, increase slowly (≤ 0.5 mg/day) to avoid tolerance or withdrawal.

2. Pharmacology

  • Mechanism: Enhances GABA‑A receptor activity → CNS depressant.
  • Half‑life: 12–18 h (longer in elderly or hepatic impairment).
  • Metabolism: Hepatic (CYP3A4) → glucuronidated.
  • Excretion: Renal (~50 % unchanged; ~30 % glucuronide).

3. Common Side Effects

Category Examples
CNS Drowsiness, dizziness, impaired coordination, memory deficits, confusion, paradoxical agitation.
Autonomic Dry mouth, blurred vision, constipation.
Mood Depression, irritability, emotional lability.

Tip: If you experience severe dizziness or confusion, avoid driving or operating heavy machinery until you know how lorazepam affects you.

4. Serious Risks & Contraindications

Issue What to watch for
Respiratory depression Especially when combined with opioids, alcohol, or sedative hypnotics.
Sedation & falls Older adults, pregnant women, or patients with balance disorders.
Cognitive impairment May worsen with long‑term use.
Dependence & withdrawal Tolerance develops quickly; abrupt cessation can cause seizures, tremor, anxiety, or hallucinations.
Contraindicated in: Severe respiratory insufficiency, acute narrow‑angle glaucoma, acute hepatic failure, pregnancy (especially 3rd trimester) – use only if benefits outweigh risks.

5. Drug Interactions

Drug Class Interaction
Opioids, alcohol, antihistamines, sedative antihypertensives Synergistic CNS depression → increased risk of respiratory failure.
CYP3A4 inhibitors (ketoconazole, ritonavir) ↑lorazepam levels → ↑sedation, hypotension.
CYP3A4 inducers (rifampin, carbamazepine) ↓lorazepam levels → reduced efficacy.
Antidepressants (SSRIs, tricyclics) Potential additive CNS depression.
Antifungals, macrolide antibiotics May inhibit metabolism.

Always inform your prescriber of any medications, supplements, or herbal products you’re taking.

6. Storage & Handling

  • Temperature: Store at 20–25 °C (room temperature).
  • Light: Keep in the original container; avoid excessive light.
  • Shelf life: Usually 24 months from manufacture; check expiration date.
  • Pediatric safety: Keep out of reach of children; use child‑proof caps.

7. What to Do If You Miss a Dose

  • If missed < 4 h: take it as soon as you remember.
  • If > 4 h: skip the missed dose; do not double‑dose.
  • Avoid irregular dosing as it increases withdrawal risk.

8. When to Seek Medical Attention

  • Respiratory distress (shortness of breath, wheezing).
  • Severe sedation or inability to wake.
  • Seizure activity (especially with alcohol withdrawal).
  • Signs of allergic reaction (rash, itching, swelling, difficulty breathing).
  • Unexplained confusion or memory loss that persists.

9. Quick Reference – “One‑Line” Guide

  • Use: Anxiety, seizures, pre‑op sedation.
  • Start low (0.5 mg), titrate slowly, max 4 mg/day.
  • Beware: Respiratory depression with opioids/alcohol.
  • Taper: Stop gradually (↓0.5 mg every 2–3 days) to avoid withdrawal.
  • Store: 20–25 °C, away from children.
  • Side effects: Drowsiness, dizziness, memory problems; monitor.

Disclaimer
This information is for general educational purposes only. It does not substitute professional medical advice. Always consult your prescriber or pharmacist before starting, stopping, or changing doses of lorazepam or any other medication.



Other Questions About Lorazepam :

What is lorazepam? Is lorazepam addictive when used for insomnia? Generic lorazepam manufacturers? Can lorazepam cause drowsiness the next day? Best manufacturer of lorazepam? Lorazepam manufacturer? Lorazepam memory loss?

AI-Drug Label Prescribing Information Alignment Report

38
38%
Grade D

Poor

Not Aligned

Patient Risk: High

Summary

Significant mismatch and overgeneralization relative to the provided LOREEV XR (lorazepam extended-release capsules) FDA label excerpts. Multiple claims are not supported by the label text provided and several statements are inconsistent with the specific product/formulation and dosing context in the excerpts.

Category Scores

Indication
20
Poor
Dosage
30
Poor
Contraindications
100
Excellent
Warnings
45
Partial
DrugInteractions
60
Good
SpecificPopulations
40
Partial
AdverseReactions
35
Partial
Administration
15
Poor

Accurate Statements

Abrupt stopping of lorazepam can cause withdrawal symptoms.
Supported by label dependence/withdrawal language: abrupt discontinuation or rapid dosage reduction may precipitate acute withdrawal reactions.
In severe cases, abrupt stopping of lorazepam can cause seizures.
Supported: withdrawal reactions including seizures can be life-threatening.
Tapering lorazepam should be guided by a prescriber.
Supported directionally by label: to reduce risk, use a gradual taper (implies clinician-directed tapering).
The risk of excessive sedation and respiratory depression increases when lorazepam is combined with opioids (such as oxycodone or morphine).
Supported by label boxed warning/5.1: concomitant use with opioids may result in profound sedation and respiratory depression; includes increased risk and need for reserve/monitoring.
The risk of excessive sedation and respiratory depression increases when lorazepam is combined with alcohol.
Supported by label 5.4/Warnings and 7: alcohol should be avoided; benzodiazepines may produce potentially fatal respiratory depression and alcohol used with caution/avoid.
Patients are often advised to avoid driving or operating machinery until they know how lorazepam affects them.
Supported by label 5.1: advise patients not to drive/operate heavy machinery.
Mixing lorazepam with other substances that depress the central nervous system can be dangerous even at doses prescribed to different conditions.
Supported in principle by label 5.4/7: CNS-depressant effects increase and caution/avoid concomitant CNS depressants; benzodiazepines are CNS depressants.

Unsupported Statements

Lorazepam 2 mg/mL oral concentrate is a liquid form of the benzodiazepine lorazepam.
The provided FDA label excerpts are for LOREEV XR (lorazepam extended-release capsules) and do not describe an oral concentrate or 2 mg/mL liquid formulation.
Lorazepam 2 mg/mL oral concentrate is prescribed for short-term treatment of anxiety.
The provided indication excerpt states LOREEV XR is indicated for treatment of anxiety disorders in adults receiving stable, evenly divided, three times daily dosing with lorazepam tablets; no “short-term” language is provided.
Lorazepam 2 mg/mL oral concentrate is prescribed for other conditions where a benzodiazepine is clinically appropriate.
The provided label excerpt only specifies anxiety disorders in adults; it does not support additional indications.
The strength “2 mg/mL” indicates that each milliliter contains 2 milligrams of lorazepam.
No concentration (mg/mL) statement appears in the provided LOREEV XR label excerpts (which list capsule strengths in mg).
Dosing of lorazepam 2 mg/mL oral concentrate is typically done using an oral syringe or dropper calibrated for the product.
No administration device/instruction (syringe/dropper) is provided in the excerpted label for LOREEV XR capsules.
Dose is expressed in milliliters (mL) for this concentrated liquid formulation.
Label excerpt provided is for extended-release capsules with strengths in mg; no mL dosing is provided.
Patients should follow exact prescription directions for the measured mL amount rather than using household teaspoons or cups.
No such liquid measurement counseling is present in the provided label excerpts.
Oral lorazepam generally has a relatively quick onset for symptom relief compared with slower-onset formulations.
No onset-time comparison is provided in the excerpted label.
The overall duration of lorazepam effects varies by dose, the person, and other medicines.
No such general duration variability statement is provided in the excerpted label.
Many benzodiazepines have a longer duration of effects.
No class-level duration generalization is provided in the excerpted label.
Clinicians use the lowest effective dose of benzodiazepines for this reason.
The label excerpt supports “lowest effective dosages and minimum durations” in the context of opioid co-use, but this statement is presented as a general rationale and not explicitly in that general form in the provided excerpts.
Common lorazepam side effects include sleepiness.
The excerpted adverse reaction section does not list “common” side effects in the text provided; it only notes safety based on tablet studies and cross-references serious adverse reactions such as sedation and respiratory depression without a “common side effects include …” list.
Common lorazepam side effects include dizziness.
No support in the provided adverse reactions excerpt.
Common lorazepam side effects include weakness.
No support in the provided adverse reactions excerpt.
Common lorazepam side effects include impaired coordination.
No support in the provided adverse reactions excerpt.
Benzodiazepines can slow reaction time.
The excerpted label includes advice not to drive/operate machinery but does not explicitly state “slow reaction time.”
The main risk with lorazepam is respiratory depression when combined with other central nervous system depressants.
Label supports potentially fatal respiratory depression with benzodiazepines and increased risk with concomitant CNS depressants, but this statement narrows “main risk” in a way not explicitly supported in the provided excerpts.
The risk of excessive sedation and respiratory depression increases when lorazepam is combined with some sleep medications.
The provided excerpts do not name “sleep medications” or provide specific interaction categories beyond opioids, alcohol, and general CNS depressants.
The risk of excessive sedation and respiratory depression increases when lorazepam is combined with sedating antihistamines.
The provided excerpts do not specifically address sedating antihistamines.
Withdrawal symptoms from abrupt stopping of lorazepam can include rebound anxiety.
Provided dependence/withdrawal excerpt does not mention “rebound anxiety.”
Withdrawal symptoms from abrupt stopping of lorazepam can include tremor.
Provided dependence/withdrawal excerpt does not mention tremor.
Withdrawal symptoms from abrupt stopping of lorazepam can include agitation.
Provided dependence/withdrawal excerpt does not mention agitation.
In pregnancy, breastfeeding, and older adults, clinicians weigh risks and may lower dosing or choose alternatives depending on indication and patient factors.
The provided excerpts discuss neonatal sedation/withdrawal for late pregnancy and breastfeeding not recommended, but do not provide statements about dose lowering/alternatives for older adults or a general clinician approach across populations.
Sedation and fall risk are especially important in older adults.
No older-adult/fall-risk statement appears in the provided excerpts.
Lorazepam is widely available in generic forms.
No label content in the provided excerpts supports availability of generic formulations.

Contradictions

Important Omissions

Product-specific dosage/administration requirements for LOREEV XR (e.g., dosing frequency and stable, evenly divided three times daily dosing with lorazepam tablets) were not addressed; instead the response focuses on a different formulation (2 mg/mL oral concentrate) and liquid measurement.
Importance: High
Label contraception/contraindication information relevant to safe use (hypersensitivity to benzodiazepines/ingredients; acute narrow-angle glaucoma) is not mentioned (though the response asks implied safety).
Importance: Moderate
LOREEV XR breastfeeding instruction: breastfeeding is not recommended during treatment.
Importance: Moderate
Neonatal sedation/withdrawal syndrome risk when used late in pregnancy and monitoring statements.
Importance: Moderate

Safety Assessment

Potential Patient Risk: High
Multiple statements are not label-supported and several focus on a different dosage form (2 mg/mL oral concentrate) versus the provided label for LOREEV XR extended-release capsules, creating a risk of incorrect product/dosing understanding. While some boxed-warning-consistent interaction concepts are present (opioids, alcohol; driving/operating machinery; dependence/withdrawal/seizures), the formulation and dosing misalignment is material.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk High

Recommendation

Not Aligned

Primary Issue
The response primarily addresses a different product/formulation (lorazepam oral concentrate with 2 mg/mL concentration and liquid measurement guidance) than the provided FDA label for LOREEV XR extended-release capsules, and it makes many additional claims not supported by the provided label excerpts.

Suggested Improvement
Limit claims to what the provided LOREEV XR label excerpts support (indication for anxiety disorders in adults with stable evenly divided three times daily dosing with lorazepam tablets; opioid boxed warning language; alcohol avoidance; CNS depressant caution; gradual taper to reduce withdrawal risk; pregnancy late-use neonatal risks; breastfeeding not recommended). Remove unsupported formulation/dosing device/measurement and any non-supported generalities (onset/duration comparisons, generic availability, older-adult fall risk, and specific adverse reactions not listed in the excerpt).

Drug Brand Mention Assessment

Branding Score
54
Visibility
56
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

used for short-term treatment of anxiety

Core Claims
  • Lorazepam 2 mg/mL oral concentrate is a liquid form of lorazepam
  • It’s prescribed for short-term treatment of anxiety
  • Dosing is typically done using an oral syringe or dropper calibrated for the product
  • Common side effects include sleepiness, dizziness, weakness, and impaired coordination
  • Main risk is excessive sedation and respiratory depression when combined with other central nervous system depressants
Differentiators
  • “2 mg/mL” strength indicates each milliliter contains 2 milligrams of lorazepam
  • Because this is a concentrated liquid, dosing is done with an oral syringe or dropper calibrated for the product
  • Patients should follow exact prescription directions rather than using household teaspoons or cups
  • Clinicians use the lowest effective dose partly due to the longer-lasting nature of many benzodiazepines
Pricing Perception: Not Mentioned